AU2003299807A1 - Heteroarylalkanoic acids as integrin receptor antagonists - Google Patents

Heteroarylalkanoic acids as integrin receptor antagonists

Info

Publication number
AU2003299807A1
AU2003299807A1 AU2003299807A AU2003299807A AU2003299807A1 AU 2003299807 A1 AU2003299807 A1 AU 2003299807A1 AU 2003299807 A AU2003299807 A AU 2003299807A AU 2003299807 A AU2003299807 A AU 2003299807A AU 2003299807 A1 AU2003299807 A1 AU 2003299807A1
Authority
AU
Australia
Prior art keywords
receptor antagonists
integrin receptor
heteroarylalkanoic
acids
heteroarylalkanoic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003299807A
Other languages
English (en)
Inventor
Mark L. Boys
Nizal S. Chandrakumar
Barbara B. Chen
Michael Clare
Bipinchandra N. Desai
Balekudru Devadas
Victoria Downs
Glen J. Gesicki
Renee M. Huff
Ish K. Khanna
Albert Khilevich
Hwang-Fun Lu
Scott B. Mohler
Srinivasan R. Nagarajan
Maria Nguyen
Mihir D. Parikh
Thomas D. Penning
Mark Russell
Lori A. Schretzman
Dale P. Spangler
Heather Stenmark
Michael B. Tollefson
Yaping Wang
John A. Wendt
Lisa Wu
Yi Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2003299807A1 publication Critical patent/AU2003299807A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2003299807A 2002-12-20 2003-12-22 Heteroarylalkanoic acids as integrin receptor antagonists Abandoned AU2003299807A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43546702P 2002-12-20 2002-12-20
US60/435,467 2002-12-20
PCT/US2003/040898 WO2004058254A1 (en) 2002-12-20 2003-12-22 Heteroarylalkanoic acids as integrin receptor antagonists

Publications (1)

Publication Number Publication Date
AU2003299807A1 true AU2003299807A1 (en) 2004-07-22

Family

ID=32682246

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299807A Abandoned AU2003299807A1 (en) 2002-12-20 2003-12-22 Heteroarylalkanoic acids as integrin receptor antagonists

Country Status (8)

Country Link
US (1) US20050043344A1 (https=)
EP (1) EP1592421A1 (https=)
JP (1) JP2006518333A (https=)
AU (1) AU2003299807A1 (https=)
BR (1) BR0317600A (https=)
CA (1) CA2507699A1 (https=)
MX (1) MXPA05006727A (https=)
WO (1) WO2004058254A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
AU2006332694A1 (en) * 2005-12-30 2007-07-12 Alantos Pharmaceuticals, Holding, Inc. Substituted bis-amide metalloprotease inhibitors
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
ES2457822T3 (es) * 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
CN102381961B (zh) * 2011-09-03 2014-01-15 四川大学 3-苯基戊二酸类化合物、其制备方法和用途
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
HRP20171873T1 (hr) 2013-02-07 2018-02-23 Scifluor Life Sciences, Inc Fluorinirani antagonisti integrina
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
PL3050878T3 (pl) 2013-09-24 2022-01-24 Fujifilm Corporation Zawierający atom azotu związek lub jego sól, lub ich kompleks z metalem
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
KR102647026B1 (ko) 2015-02-19 2024-03-12 사이플루어 라이프 사이언시즈, 인크 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
WO2018089353A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as alpha v integrin inhibitors
CN110177787A (zh) * 2016-12-29 2019-08-27 圣路易斯大学 整合素拮抗剂
ES2904645T3 (es) * 2017-11-07 2022-04-05 Bristol Myers Squibb Co Derivados de pirrolopirazina como inhibidores de integrina alfa v
CN115872926A (zh) * 2021-09-26 2023-03-31 南通诺泰生物医药技术有限公司 三唑类抗真菌药及其中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
PT889877E (pt) * 1996-03-29 2002-02-28 Searle & Co Derivados fenileno meta substituidos e sua utilizacao como antagonitas ou inibidores integrina alfa v beta3
DE69713582T2 (de) * 1996-03-29 2003-01-09 G.D. Searle & Co., Chicago Zimtsäurederivate und deren verwendung als integrin-antagonisten
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
EP1049693A1 (en) * 1997-11-26 2000-11-08 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
CA2443332A1 (en) * 2001-04-04 2002-10-17 University Of Rochester .alpha..nu..beta.3 integrin-binding polypeptide monobodies and their use
US6750215B2 (en) * 2001-08-08 2004-06-15 Pharmacia & Upjohn, S.P.A. Substituted benzoxazines as integrin antagonists

Also Published As

Publication number Publication date
WO2004058254A1 (en) 2004-07-15
JP2006518333A (ja) 2006-08-10
EP1592421A1 (en) 2005-11-09
CA2507699A1 (en) 2004-07-15
MXPA05006727A (es) 2005-09-08
US20050043344A1 (en) 2005-02-24
BR0317600A (pt) 2005-11-29

Similar Documents

Publication Publication Date Title
AU2003299807A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AU2001269876A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AU2003261392A1 (en) M3muscarinic acetylcholine receptor antagonists
AU2003241836A1 (en) Lpa receptor antagonists
IL165841A0 (en) Mchir antagonists
AU2003259267A1 (en) Substituted aminopyrimidines as neurokinin antagonists
AU2003231513A1 (en) Pgd2 receptor antagonist
AU2002341834A1 (en) Antagonists
AUPR833401A0 (en) G protein-coupled receptor antagonists
AU2001269821A1 (en) Cycloalkyl alkanoic acids as integrin receptor antagonists
AU2003251739A1 (en) New neuropeptide y y5 receptor antagonists
AU2003255501A1 (en) Cxcr4 receptor antagonists
AU2001290772A1 (en) Alpha v integrin receptor antagonists
AU2003291959A1 (en) Novel glucagon antagonists
AU2541000A (en) Beta-phenylalanine derivatives as integrin antagonists
AU2002220598A1 (en) Beta-amino acid derivatives as integrin receptor antagonists
AU6990000A (en) Novel integrin receptor antagonists
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU6221201A (en) Propanoic acid derivatives as integrin receptor antagonists
AU2002347552A1 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2003240705A1 (en) Morpholinylmethylureas ccr-3 receptor antagonists
AU2003287219A1 (en) Il-8 receptor antagonists
AU2003297408A1 (en) Thiazole compounds as integrin receptor antagonists derivatives
IL162534A0 (en) Novel alkansulfonamides as endotheline antagonists
AU2003223329A1 (en) Antagonists of rf-amide neuropeptides

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase